Allarity Board Authorizes Share Repurchase Program

(RTTNews) - Allarity Therapeutics (ALLR) announced that its Board has authorized a share repurchase program, allowing for the repurchase of up to $5 million of common stock through February 28, 2026.

"The decision reflects our confidence in the company's long-term vision, the clinical potential of stenoparib, and our ability to advance its development to provide a much-needed treatment option for women battling advanced ovarian cancer," said Allarity CEO Thomas Jensen.

Allarity said its cash position allows to maintain a financial runway extending into 2026. The company said it remains sufficiently capitalized to proceed with the share repurchase program without affecting this runway.

For More Such Health News, visit rttnews.com.